Google Search
| 产品数据 | 评论 | 实验方法 |
表达宿主: Human Cells |   |
表达宿主: Human Cells | |
表达宿主: Human Cells | |
表达宿主: Human Cells | |
表达宿主: Human Cells | |
反应性: Human 应用 : ELISA | |
反应性: Human 应用 : WB | |
-HB04OC2702-WB.png)
反应性: Human 应用 : | |
-HD09MA2513-WB.png)
-HD09MA2513-1ug-NIH-3T3-IF.png)
-HD09MA2513-IP.png)
反应性: Mouse 应用 : | |
反应性: Mouse 应用 : ELISA | |
反应性: Mouse 应用 : ELISA | |
反应性: Mouse 应用 : ELISA | |
反应性: Mouse 应用 : ELISA | |
VCAM1/VCAM-1/CD106 细胞裂解液 Related Products
Related Products
Featured Reagent Products
VCAM1/VCAM-1/CD106 lysate_category 研究背景
Vascular cell adhesion molecule 1 (VCAM-1), also known as CD106, is a cell surface sialoglycoprotein belonging to the immunoglobulin superfamily. Two forms of VCAM-1 with either six or seven extracellular Ig-like domains are generated by alternative splicing, with the longer form predominant. VCAM-1 is an endothelial ligand for very late antigen-4 (VLA-4) and α4ß7 integrin expressed on leukocytes, and thus mediates leukocyte-endothelial cell adhesion and signal transduction. VCAM-1 expression is induced on endothelial cells during inflammatory bowel disease, atherosclerosis, allograft rejection, infection, and asthmatic responses. During these responses, VCAM-1 forms a scaffold for leukocyte migration. VCAM-1 also activates signals within endothelial cells resulting in the opening of an "endothelial cell gate" through which leukocytes migrate. VCAM-1 has been identified as a potential anti-inflammatory therapeutic target, the hypothesis being that reduced expression of VCAM-1 will slow the development of atherosclerosis. In addition, VCAM-1-activated signals in endothelial cells are regulated by cytokines indicating that it is important to consider both endothelial cell adhesion molecule expression and function during inflammatory processes.
Immune Checkpoint Immunotherapy Cancer Immunotherapy Targeted Therapy
人 VCAM1/VCAM-1/CD106 lysate_category 参考资料
请注意：所有产品都是“仅用于科研，而不能用于诊断或治疗用途”
